and everyone listening a promising our We start Thank you, we'll and our progress We're cover call to of a what report joining update. the X. good pleased brief launch thank in start you with during you Starting us to this XXXX Jonathan, chronic morning. joining quarter for to quarter. appreciate second outline for us on today. I'll sinusitis Slide our
takeaways from key call. review I'll X First, today's
to new Spence, Specialist and of and Paul encouraging clinical physician that early future Chief efforts audience Commercial Second, will ENT discuss uptake. XHANCE's enable Officer, Allergy will our progress some signals profile on our our educate early
Investor our of Development, full second XXXX our quarter guidance VP will our financial XXXX. performance Business Relations and and review Neely, for Jonathan Next, year
your and to up questions. the return wrap call we'll take Finally,
X highlight presentation. I'd like Slide to key to today's takeaways Turning X. from
both First, we to Claims the that frequently is nasal long-term currently reiterate launching XXx sinusitis set providers into our by chronic potential least polyps. us, prescribers. the opportunity been team, data significant XHANCE second has training which of of to In believe meeting years interacting like engaged in new complete reshape more diagnosed a in the we of universe quarter. national healthcare and business of materials at than held by and started and sinusitis new have now of a future. chronic for I'd potential with familiar they to the full Reshaping sales with suggests in our our are front April, being sales the business
by efforts peak based year force on sinusitis and As accompanied XXXX. promotion at new operations a with nonpersonal to attaining reminder, year educational materials arming income with of our our of team for current million promotional infrastructure, is suite label, launch $XXX the sales and and with full from of our new plan chronic sales the positive digital producing by a objective least sales
quarters, seeking preparing since in efficiency, operating increasing opportunity for our been stabilizing X the the has I focus chronic approval revenue on the this the Over and XHANCE's on greatly expanded organization our sinusitis. accepted chronic prior first-and-only course of on indication new on greatly for responsibility sinusitis for position, our
net the financial are revenue this XXXX.
From launch than year the we a of prescription. initial Our improving success second team this building balance our stronger in per of these efforts areas in had start on perspective, and base a significantly quarter a expenses by stronger sheet, includes at commercial means lower that average
resulting the our are from greatly strength our aiming begin while and addressable new foundation of on building few operating first quarters to penetrate indication. launch, market, the efficiency the we first-and-only to to During sustain expanded CS gains, total
quarters was are XHANCE Express and to second pleased Over that quarter, Scripts' late large launch, expected the in coverage initial we added insurance improving national gradually after formularies.
sales You'll clinical hear second new more materials about for data that new underserved our gradual also should part force empowered and facilitate a of quarter, to XHANCE and the treating clinical differentiated adoption and interactions use to moment.
In a in promotional begin the engage regular we prescribers this that practice as disease. educational of
progress or the earlier of as we expect HUB. few our transition noted, quarters making of realize we're to quarter able our our first optimize foundation work we first believe of the much fulfillment reporting intake continue central the And effectiveness fulfillment a new of on we revenue our in XHANCE to year, be necessary have long-term that prescription addition, and we we're to potential Overall, previously with on expectations. consistent of to during laying to began achieved launch In launch, this the channel. significant the pharmacy market.
Today, to
by his team Chief will a about just updates Paul Our encouraging Commercial Officer, in progress provide Spence, initial moment. some
clinical first few after will gradual coverage growth implement the we educate on believe steadily the to quarters to related target indication. continue new We launch data and prescribers while insurance progressively produce changes
We for execution continue larger on of that been now the to to acceleration in believe has growth the that will XHANCE. market lead future much opened multiple consistent fronts trajectory commercial plan
lower profitable first successful in away during business we more our on we Lastly, and move business. efforts have the anticipated to focus than been year, from profit and unprofitable this originally half of
we reduced to million revenue XXXX range prescription $XX at $XX represents from of to As at of year our to year full $XX at least compared million for our sustainable of XXXX co-pay result lower lines growth per to range net intentionally are The year business have $XXX, support. offsetting, expectations previous expectation of our removal It's profit reflects for more least growth the previously.
The on our million unchanged. of and increasing the changes guidance XX% XXXX profitable associated for to of which full effect believe long range the $XX revenue and to term. for business cash note that runway focusing XX% healthier, an combined largely XX% We of million. revenue leaves will a a is result, compared to full revenue business of XXXX. we expectation million narrowing revenues new unprofitable XHANCE $XX to which net narrowing to compared increase $XXX over in least operating XHANCE revenues with X also income these important in We're directionally
to and launch continue commercial recent previously over support to Spence the Finally, for to operating efforts XXXX with to communicated.
I'd call we year to full in plan Paul? respect expense, incremental of year turn modestly promotional be Paul highlights. as to launch like XXXX now full performance review initial to
